Leem, Sun-Hee

Professor Sun-Hee Leem, PhD

Biographical Information

Sun-Hee Leem attended Dong-A University obtaining a B.Sc. and M.Sc. in the Department of Biology. She received the Ph.D. degree in Physiology at Osaka University in Japan, 1992. She was an assistant professor in Osaka University in Japan (1993 - 1995) and received JSPS fellowship (1992-1993). Then she was invited as a Korea-Japan Brain-Pool Program Scientist Post-doctoral Fellow at Korea Basic Science Institute, Daejon, Korea (1995-1996). She was employed as a visiting associate at Laboratory of Molecular Genetics, National Institutes of Environmental Health Sciences/National Institutes of Health (NIEHS/NIH) (1999-2000). Now she is employed as a professor in the Graduate School of Dong-A University in Busan, Korea since 2000 including the leave for a Research Fellow in NCI (National Cancer Institute)/NIH (Co PI; Involved in Human Genome Project, Chromosome 19) in USA (2002 - 2004). She is a project leader for projects supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT & Future Planning since the year 2020. She has published over 130 peer-reviewed papers and obtained dozens of patents. Her current interests are the mechanism of anticancer drug resistance, discovery of biomarkers to be used for bladder cancer diagnosis and toxicity of air pollution particles.

Ten selected published papers

E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair. Mun JY, Baek SW, Park WY, Kim WT, Kim SK, Roh YG, Jeong MS, Yang GE, Lee JH, Chung JW, Choi YH, Chu IS, Leem SH. Int J Mol Sci. 2020 Nov 27;21(23):E9025.
Fanconi Anemia Pathway Activation by FOXM1 Is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance. Roh YG, Mun JY, Kim SK, Park W, Jeong MS, Kim TN, Kim WT, Choi YH, Chu IS, Leem SH. Cancers (Basel). 2020 May 30;12(6):E1417.
Genomic Signature of the Standardized Uptake Value in 18F-Fluorodeoxyglucose Positron Emission Tomography in Breast Cancer. Kim SK, Ahn SG, Mun JY, Jeong MS, Bae SJ, Lee JS, Jeong J, Leem SH*, Chu IS* (*co-corresponding). Cancers (Basel). 2020 Feb 20;12(2)
Identification of an immunotherapy-responsive molecular subtype of bladder cancer. Song BN, Kim SK, Mun JY, Choi YD, Leem SH*, Chu IS*. EBioMedicine. 2019 Dec;50:238-245. doi: 10.1016/j.ebiom.2019.10.058. Epub 2019 Nov 15.
Thymoquinone-Induced Tristetraprolin Inhibits Tumor Growth and Metastasis through Destabilization of MUC4 mRNA. Lee SR, Mun JY, Jeong MS, Lee HH, Roh YG, Kim WT, Kim MH, Heo J, Choi YH, Kim SJ, Cha HJ, Jun M, Leem SH. Int J Mol Sci. 2019 May 28;20(11) 2614..
A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility. Yoon SL, Roh YG, Chu IS, Heo J, Kim SI, Chang H, Kang TH, Chung JW, Koh SS, Larionov V, Leem SH. Exp Mol Med. 2016 Jul 15;48(7):e246
Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer. Lee SR, Roh YG, Kim SK, Lee JS, Seol SY, Lee HH, Kim WT, Kim WJ, Heo J, Cha HJ, Kang TH, Chung JW, Chu IS, Leem SH. Clin Cancer Res. 2015, 21(23): 5391-5403.
Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer. Kim SK, Roh YG, Park K, Kang TH, Kim WJ, Lee JS, Leem SH*, Chu IS*, Clin Cancer Res. 2014, 20(12):3233-43.
Modulation of ATR-mediated DNA damage checkpoint response by cryptochrome 1. Kang TH, Leem SH. Nucleic Acids Res. 2014, 42(7):4427-4434.
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology. 2012. 55(5):1443-1452. Kim SM*, Leem SH*, Chu IS*, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. (*equal contribution)

<style>

p{
	font-family:

}

.p1
{
	font-size:14px;
	line-height:150%;
}

.p2
{
	font-size:17px;
	line-height:150%;
}

</style>

<h2 class="bullet">Professor Sun-Hee Leem, PhD</h2>

Biographical Information 
 Sun-Hee Leem attended Dong-A University obtaining a B.Sc. and M.Sc. in the Department of Biology. She received the Ph.D. degree in Physiology at Osaka University in Japan, 1992. She was an assistant professor in Osaka University in Japan (1993 - 1995) and received JSPS fellowship (1992-1993). Then she was invited as a Korea-Japan Brain-Pool Program Scientist Post-doctoral Fellow at Korea Basic Science Institute, Daejon, Korea (1995-1996). She was employed as a visiting associate at Laboratory of Molecular Genetics, National Institutes of Environmental Health Sciences/National Institutes of Health (NIEHS/NIH) (1999-2000). Now she is employed as a professor in the Graduate School of Dong-A University in Busan, Korea since 2000 including the leave for a Research Fellow in NCI (National Cancer Institute)/NIH (Co PI; Involved in Human Genome Project, Chromosome 19) in USA (2002 - 2004). She is a project leader for projects supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT & Future Planning since the year 2020. She has published over 130 peer-reviewed papers and obtained dozens of patents. Her current interests are the mechanism of anticancer drug resistance, discovery of biomarkers to be used for bladder cancer diagnosis and toxicity of air pollution particles. 
Ten selected published papers 
<ol>
 <li>E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair. Mun JY, Baek SW, Park WY, Kim WT, Kim SK, Roh YG, Jeong MS, Yang GE, Lee JH, Chung JW, Choi YH, Chu IS, Leem SH. Int J Mol Sci. 2020 Nov 27;21(23):E9025.</li>
 <li>Fanconi Anemia Pathway Activation by FOXM1 Is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance. Roh YG, Mun JY, Kim SK, Park W, Jeong MS, Kim TN, Kim WT, Choi YH, Chu IS, Leem SH. Cancers (Basel). 2020 May 30;12(6):E1417.</li>
 <li>Genomic Signature of the Standardized Uptake Value in 18F-Fluorodeoxyglucose Positron Emission Tomography in Breast Cancer. Kim SK, Ahn SG, Mun JY, Jeong MS, Bae SJ, Lee JS, Jeong J, Leem SH*, Chu IS* (*co-corresponding). Cancers (Basel). 2020 Feb 20;12(2)</li>
 <li>Identification of an immunotherapy-responsive molecular subtype of bladder cancer. Song BN, Kim SK, Mun JY, Choi YD, Leem SH*, Chu IS*. EBioMedicine. 2019 Dec;50:238-245. doi: 10.1016/j.ebiom.2019.10.058. Epub 2019 Nov 15.</li>
 <li>Thymoquinone-Induced Tristetraprolin Inhibits Tumor Growth and Metastasis through Destabilization of MUC4 mRNA. Lee SR, Mun JY, Jeong MS, Lee HH, Roh YG, Kim WT, Kim MH, Heo J, Choi YH, Kim SJ, Cha HJ, Jun M, Leem SH. Int J Mol Sci. 2019 May 28;20(11) 2614..</li>
 <li>A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility. Yoon SL, Roh YG, Chu IS, Heo J, Kim SI, Chang H, Kang TH, Chung JW, Koh SS, Larionov V, Leem SH. Exp Mol Med. 2016 Jul 15;48(7):e246</li>
 <li>Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer. Lee SR, Roh YG, Kim SK, Lee JS, Seol SY, Lee HH, Kim WT, Kim WJ, Heo J, Cha HJ, Kang TH, Chung JW, Chu IS, Leem SH. Clin Cancer Res. 2015, 21(23): 5391-5403.</li>
 <li>Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer. Kim SK, Roh YG, Park K, Kang TH, Kim WJ, Lee JS, Leem SH*, Chu IS*, Clin Cancer Res. 2014, 20(12):3233-43.</li>
 <li>Modulation of ATR-mediated DNA damage checkpoint response by cryptochrome 1. Kang TH, Leem SH. Nucleic Acids Res. 2014, 42(7):4427-4434.</li>
 <li>Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology. 2012. 55(5):1443-1452. Kim SM*, Leem SH*, Chu IS*, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. (*equal contribution)</li>
</ol>